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The genetic basis for didanosine (ddI) resistance in human immunodefeciency virus (HIV-1) has previously been shown
to be commonly associated with a Leu to Val change at codon 74 in the HIV-1 RT gene. In this study sequential viral isolates
were analyzed from five patients with prior zidovudine (AZT) use who received 6 to 16 months of ddI therapy. Following
ddI therapy, viral isolates exhibited an increased AZT susceptibility and decreased ddI susceptibility. Sequence and nested
PCR analysis of the HIV-1 RT gene revealed that two viral isolates contained the Leu to Val change at codon 74, and three
other isolates with reduced susceptibility to ddI each contained changes at codons 65, 70, and 72. Site-directed mutagenesis
was employed to insert specific mutations in RT gene of proviral clone pNL4-3. Analysis of virion-associated reverse
transcriptase activity indicated that the Lys70Arg mutation resulted in an enzyme with 2- to 4-fold decreased susceptibility
to ddATP. Statistical analysis of the inhibitory concentration for RT activity between pNL4-3 and mutant Lys70Arg viruses
obtained in three independent RT inhibition assays was significant (P  0.05) by student t test paired analysis. Drug
susceptibility assays on the virus with Lys70Arg mutation showed a marginal decrease in susceptibility to ddI (1.5- to 2-
fold) and about 4- to 6-fold decrease in susceptibilty to AZT. Mutations Lys65Glu and Arg72Ser resulted in an impaired RT
with greatly diminished functional RT activity. The AZT-associated Lys70Arg mutation results in an RT enzyme with decreased
susceptibility to ddATP. q 1996 Academic Press, Inc.
Resistance to Zidovudine (AZT) in human immuno- The mechanism of the development of ddI resistance
conferred by mutations Lys65Arg, Leu74Val, and Met184-defeciency virus type-1 (HIV-1) is associated with five
Val has been studied using recombinant mutant RTs andmajor mutations in the polymerase domain of reverse
the incorporation of dNTPs or ddITP in in vitro RT assaystranscriptase (RT) [Met41Leu, Asp67Asn, Lys70Arg,
(11, 15–17). The mutation Thr69Asp in RT is associatedThr215Tyr/Phe, Lys219Gln]. The mutation Lys70Arg
with resistance to ddC and no cross-resistance to ddI oralone in the virus confers a 4- to 8-fold decreased sus-
AZT is conferred by this mutation (3). Cross-resistancecepitibilty to AZT and is the first to occur in patients
between ddI and ddC has been shown with mutationsreceiving AZT as monotherapy (1, 2). Didanosine (ddI,
Leu74Val and Met184Val, but cross-resistance between2*,3*-dideoxyinosine) and zalacitabine (ddC, 2*,3*-dideox-
AZT and ddI in clinical isolates using cell culture assaysycytidine) have also been developed to treat HIV-1 infec-
has been infrequently reported (18–21). Cross-resis-tion (3–5), and strains of HIV-1 with reduced susceptibilty
tance has not previously been documented in a homoge-to ddI have emerged in patients who were switched to
nous population of cloned viruses. The clinical signifi-ddI after treatment with AZT (6–8). Resistance of HIV-1
cance of resistance of HIV-1 to AZT is now clearly associ-to ddI has been associated with a single nucleotide
ated with a poor prognosis (22). In this present study,change in the RT gene at codon 74 (Leu r Val) (9) and
we have analyzed the HIV-1 isolates from five patientsthe mutations Lys65Arg, Gln151Met, and Met184Val have
who were on AZT treatment for several months and thenalso conferred decreased susceptibilty to ddI (10–12).
switched to ddI. By using site-directed mutagenesis andThe decreased susceptibility to ddI due to a stavudine
an assay of virion associated RT, we have shown that(d4T, deoxy 4* thymidine)-related mutation Val75Thr has
the mutation Lys70Arg results in an altered HIV-1 RT withalso been reported (13) but not confirmed in patients
decreased susceptibility to ddATP.receiving stavudine (14).
Sequential HIV-1 isolates were collected from 42 sub-
jects enrolled in a clinical trial of ddI therapy at Beth
Israel Hospital for patients who were intolerant of AZT1 To whom correspondence should be addressed. Fax: (617) 667-
5541. (ACTG 118). All participants had AIDS, ARC, or asymp-
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TABLE 1
Sensitivity of Clinical HIV-1 Isolates to AZT and ddl and Mutations Observed during Pre- and Post-ddl Therapy
Prior AZT IC50 (mM)a
therapy Weeks on
Isolate (months) ddl AZT ddl Mutations
HIV-III B Wild type 0.01 2.20
Patient 1 9 0 0.22 3.76 Glu65, Gly76, Tyr 215
72 0.05 5.89 Val74, Pro116, Pro117, Phe127, Phe135
Patient 2 6 8 0.19 0.22 Mixture of WT and Tyr 215
72 0.04 6.20 Val74, Tyr 215
Patient 3 15 0 0.31 0.41 Arg70, Tyr 215
24 0.04 6.60 Arg70 and Ser72 or Arg70 and Ala72
Patient 4 8 0 0.01 0.70 Arg70
24 0.07 4.80 Ala102, Arg174
Patient 5 7 0 0.01 0.80 (Ile or Thr or Phe)175 b
24 0.17 4.20 Asp42 and Arg70 or Asp42 and Ile70)
a The IC50 values are the average of two independent drug susceptibility assays.
b Each of three independent clones analyzed by sequencing showed different amino acid changes at codon 175.
tomatic HIV-1 infection with CD4  300 mm3. Blood was additional factors, outside the RT-encoding region, may
contribute to AZT susceptibility (26). Previous reports de-collected from each study participant every 3–6 months
for HIV-1 isolation. Phenotypic drug susceptibility to AZT scribe an increase in sensitivity to AZT for clinical iso-
lates obtained from patients who were switched to ddI(Burroughs Wellcome Co., Research Triangle Park, NC)
and ddI (Calbiochem, La Jolla, CA) were performed em- therapy after an initial treatment with AZT (4, 8, 9, 19, 21,
27). The mean ddI IC50 was 0.98 mM and 1.0 mM forploying the ACTG/DoD HIV-1 Drug Susceptibility Assay
as described elsewhere (23). To detect mutations at RT subjects with6 months and6 months of AZT therapy.
Among the 18 subjects who remained on the study forcodon 74 and 215 directly from genomic DNA of pre-ddI
and post-ddI therapy samples, a nested primer strategy at least 6 months, 4 subjects had either a fourfold in-
crease in ddI IC50 between the baseline and follow-updescribed elsewhere (24, 25) was employed. The pres-
ence of mutations in the RT gene derived from clinical samples or a ddI IC50  3.0 mM (Table 1). However,
one post-ddI isolate from patient 1 showed negligibleisolates was confirmed either by cloning and sequencing
the entire RT gene by dideoxynucleotide chain termina- decrease in ddI susceptibility even in the presence of
Leu74Val mutation (Table 1). On the other hand the iso-tion (Sequenase v. 2.0 kit, USB) method or by direct PCR
amplification using Taq DyeDeoxy Terminator Cycle Se- late from patient 4 showed a sevenfold increase in ddI
IC50 in the absence of any known ddI-related mutationquencing (370A, Applied Biosystem). The observation of
the different mutation sites in clinical isolates of 5 pa- (Table 1). This indicates the large variability in ACTG/
DoD drug susceptibility assay for the measurement oftients (Table 1) in this study may be attributed to differen-
tial amplification of target DNA molecules, presence of ddI susceptibility in clinical isolates. Only a low level
(two- to fourfold) of decrease in susceptibility has beenheterogenous population of viruses, and/or selective
evolution of resistant viruses in different hosts. observed with a known ddI-related mutation Leu74Val in
cloned viruses (7, 9).Twenty-one of forty-two subjects terminated the study
before 6 months. HIV-1 was isolated from 18/21 subjects An in vitro RT inhibition assay was employed to mea-
sure directly the effects of specific mutations on the sus-who remained on the study drug for at least 6 months.
At entry into the study, the mean AZT IC50 was 1.03 mM ceptibility of RT to inhibition by ddATP, a metabolically
active form of ddI. RT codons 65 to 75 lie in the aminofor subjects with6 months of previous AZT therapy and
0.04 mM for subjects with 6 months of previous AZT terminal end of HIV-1 RT, a region that corresponds to
b3–b4 connecting loop in RT-crystal structure (28) andtherapy (P  0.008). Increased AZT susceptibility was
observed in three post-ddI isolates from patients 1, 2, mutations Lys65Arg and Leu74Val are associated with
decreased susceptibility to ddI and ddATP (9, 10, 15).and 3 (Table 1). The isolate from patient 2 showed the
presence of the ddI-related mutation Leu74Val and an Out of a panel of mutations presented in Table 1, we
have selected those which corresponds to b3–b4 regionAZT-related mutation Thr215Tyr, which explains the de-
creased susceptibility to AZT for this isolate as reported of RT for their possible role in conferring decreased sus-
ceptibility to ddI. Two of the five viral isolates containedearlier (7, 9). However, the isolates from patients 1 and
3, which also showed decreased susceptibility to AZT the Leu to Val change at codon 74 known to be associ-
ated with ddI resistance. The Lys70Arg mutation hasafter ddI treatment, carried mutations not previously
shown to suppress AZT resistance. This suggest that been associatied with an eightfold decrease in suscepti-
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TABLE 2
Oligonucleotides Used in This Study
Sr. No. Mutated RT codon Mutagenic primers Nucleotide No. WT triplet Mutant triplet
1 Lys70 r Arg 5*TTTTCTCCATCTAGTACTGTC3* (2768–2748) AAA AGA
2 Lys65 r Glu 5*CTGTCTTTTTCCTTTATGGCA3* (2752–2732) AAA GAA
3 Lys65 r Gln 5*CTGTCTTTTTGTTTATGGCA3* (2752–2732) AAA CAA
4 Leu74 r Val 5*GAAATCTACTACTTTTCTCCAT3* (2780–2759) TTA GTA
5 Arg72 r Ser 5*CTACTAATTTGCTCCATTTAGTAC3* (2775–2752) AGA AGC
6 Lys70 r Arg 5*CTACTAATTTGCTCCATCTAGTATGTC3* (2775–2748)
/ Arg72 r Ser
Sequencing primers for RT gene
5*TTGCACTTTAAATTTTCCCATT3* (2535–2555)
5*ACAATGGCCATTGACAGAAG3* (2615–2634)
5*AAGTATACTGCATTTACCATACCTAGTATA3* (2925–2954)
Note. Highlighted nucleotides were inserted to obtain the mutant codon; Nucleotide numbers in parenthesis are obtained from pNL4-3 sequence
Genbank Accession No. M19921 (42).
bility to AZT (1, 2) and it has not been previously associ- contaminating DNase or RNase activity prior to RT assay.
No such contamination was detected in our RT lysates.ated with decreased susceptibility to ddI. Three of five
patient’s pre- and post-ddI isolates showed the presence The Lys65Glu change completely interfered with the
ability of the virus to replicate, although in other reportsof the mutation Lys70Arg. We evaluated the effect of
Lys70Arg, Lys65Glu, and Arg72Ser mutations on ddI and Lys65Arg mutant is able to replicate (32, 33). Neither the
presence of p24 antigen nor any RT-activity was detectedddATP sensitivity in cloned viruses.
To insert specific point mutations in RT coding se- in supernatants harvested up to 6 weeks posttransfec-
tion. Viral clones carrying the Lys65Gln change instead ofquences Altered Sites in vitro mutagenesis system (Pro-
mega, WI) was used according to the directions provided Lys65Glu were also made and the pNL4-3 virus carrying
mutation Lys65Gln produced only 15 pg/ml of p24 anti-by the manufacturer and others (29). Briefly, a 4.3-kb
SphI–SalI fragment of proviral clone pNL4-3 was cloned gen in PBMC after 4 weeks of infection. The Arg72Ser
mutation also failed to produce p24 antigen and a con-into mutagenesis phagemid pALTERTM-1. Single-stranded
DNA from this recombinant phagemid was used to create struct carrying double mutations (Lys70Arg / Arg72Ser)
also did not replicate actively in PBMC. Similarly, thespecific mutations in RT using mutagenic oligonucleo-
tides (Table 2) which differ in one or two nucleotides double mutant constructs Lys65Glu / Lys70Arg and
Lys65Gln / Lys70Arg were unable to replicate in PBMC.from the wild-type (WT) sequence. To generate a full-
length proviral clone, the 4.3-kb SphI–SalI fragment from The presence of a heterogenous population of viruses
in patient’s samples, differential impact of backgroundpNL4-3 was replaced with the identical fragment of muta-
genic vector pALTER-1 carrying various point mutations variations in the HIV RT gene or defective proviruses in
patient’s circulating PBMC (34–36) may be associatedin RT gene. PHA-stimulated PBMC (5 1 106) were trans-
fected with 5 to 10 mg of plasmid DNA by electroporation. with the RT containing these mutations. Additionally, the
effect of the variability in the length of the side chains ofThe virus production was monitored by determining the
presence of antigen p24 by ELISA kit (Coulter or DuPont) different amino acids substituted in the RT gene on the
production of a functional polymerase cannot be ruledand by assaying the RT-activity by an in vitro RT assay
which measures the incorporation of [methyl] 3H-TTP into out (31, 37).
The mutant clones Lys70Arg and Leu74Val werecDNA of a poly(rA) template in the presence of virion
associated RT and oligo (dT) (30). Upon transfection of tested for their ability to incorporate ddATP in a cell-free
in vitro RT assay using a template-primer combinationPBMC with the full-length clone pNL4-3 and its RT-vari-
ants, Lys70Arg and Leu74Val, efficient virus production of homoploymer poly U-oligo (dA) and a substrate [a-
32P]dATP as described elsewhere (38). Percentage inhi-was seen 5 days after electroporation. In 3 weeks, the
p24 antigen concentration rose to 33, 43, and 40 ng/ml bition of RT-activity was calculated after subtracting the
background RT-activity in the absence of divalent cationin the supernatants collected from pNL4-3, Lys70Arg, and
Leu74Val transfectants, respectively. Similarly, the RT- (Mn2/) and the IC50 values for WT control and mutant
viruses were calculated using statistical program Systat.activity was 1.25 1 105, 1.2 1 105, and 1.5 1 105 cpm/
ml in a 60-min assay for RT lysates of pNL4-3, Lys70Arg, The in vitro RT assay showed a statistically significant
difference between WT and mutant RTs (Table 3 and Fig.and Leu74Val viruses, respectively. These results are in
agreement with assays employing other proviral clones 1). The average IC50 values of three independent asaays
were 1.16 { 0.04, 3.40 { 1.27, and 4.10 { 0.28 mM for(e.g., pHXBc2) for mutagenesis studies (7, 24, 31). The
viral lysates were always tested for the presence of any pNL4-3, Lys70Arg, and Leu74Val viruses, respectively.
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TABLE 3 resulted in a virus exhibiting increased AZT susceptibility
in comparision to WT pNL4-3 (Table 3). The ACTG/DoDIC50 Values for HIV Variant
assay shows approximately threefold variability when
IC50 (mM) assaying ddI resistance and there was considerable
overlap in values obtained for WT and mutant viruses.
Virion Differences in drug susceptibility of less than threefold
associated
are difficult to interpret due to the inherent variability ofACTG/DoD drug susceptibility RT based
the ACTG/DoD protocol for ddI.assay assay a
The mutation Lys70Arg was present in 7 of a total of
HIV variant AZT ddl ddATP 25 patient samples from patients who had not received
drug therapy (40). Upon analysis of quasispecies distribu-
pNL4-3 (WT) 0.13 { 0.06 4.12 { 0.65 1.16b { 0.04
tions, extensive heterogenity was observed at codon 70,Lys70Arg 0.55 { 0.10 6.85 { 3.47 3.40b { 1.27
with genomes harboring either amino acid Lys or Arg.Leu74Val 0.06 { 0.07 8.14 { 2.31 4.10b { 0.28
This finding suggests that use of AZT may select for a
Note. The values given above are the average of multiple indepen- preexisting variant pool. Our results provide evidence that
dent assays. an AZT-associated mutation Lys70Arg can result in ana Viron associated RT activity was measured in the presence of in-
altered RT with decreased susceptibility to ddATP. It iscreasing concentrations of ddATP using template-primer poly U-oligo
not possible to predict whether this level of decrease in(dA) and substrate [a-32P]dATP.
b Statistical analysis between three pairs of IC50 values was signifi- susceptibility will impact on treatment with ddI. Decreased
cant (P  0.05). susceptibility to AZT-resistant virus to dideoxynucleoside
agents containing a 3*-azido group has been reported
previously using a HeLa cell CD4 plaque assay (39).
The IC50 values were threefold higher for an RT con- The mutation Lys70Arg lies in the amino terminal end
taining Lys70Arg as compared to wild-type pNL4-3 RT of the HIV-1 RT, a region that corresponds to the b3–b4
enzyme in this assay. Statistical analysis for three pairs connecting loop (28) and our results suggest that it may
of IC50 values of pNL4-3 and Lys70Arg viruses was signif- be involved in altered interaction of enzyme with template
icant (P  0.05) by student t test. The RT containing the during cDNA synthesis similar to the mutation Leu74Val
Leu74Val mutation was included as a positive control for (41). This study provides direct evidence for the role of
the assay. In an independent assay the IC50 values for the AZT-related mutation Lys70Arg in the development
WT, Lys70Arg, and Leu74Val viral enzymes were 1.2, 2.5, of reduced susceptibility to ddATP in an RT assay. This
and 3.9 mM, respectively (Fig. 1). The WT recombinant
reverse transcriptase obtained from the AIDS Reference
Repository, used as a negative control for the assay, was
more susceptible to ddATP (IC50 0.06 mM) than virion
associated RT of WT pNL4-3 virus (IC50 0.6 mM) in an
independent assay (Table 3). The ddI-resistant mutants
showed a two- to fourfold decrease in susceptibility to
ddI or ddATP in both the cell culture and RT based in
vitro assays but the RT based assay had less variability
and showed a statistically significant difference com-
pared to WT. This differs from AZT-resistant mutants which
show a decrease in susceptibility to AZT in cell culture
assay but no change by in vitro RT assays (37, 39).
In the ACTG/DoD consensus PBMC-based drug sus-
ceptibility assay the presence of Lys70Arg was associ-
ated with a 1.5- to 2.0-fold decrease in ddI susceptibility
in comparision to control virus pNL4-3 which was not
statistically significant. The positive control virus con-
taining the Leu74Val mutation exhibited a 2.0- to 2.5-fold
decrease in ddI susceptibility as compared to WT control
pNL4-3. The average ddI IC50s from four independent
assays were 4.12 { 0.65, 6.85 { 3.47, and 8.14 { 2.31
mM for WT (pNL4-3), Lys70Arg, and Leu74Val viruses,
FIG. 1. Inhibition of RT-activity in the presence of ddATP. Virionrespectively. Similarly, the mutant virus containing Ly-
associated RT lysates were prepared from different HIV variants and
s70Arg showed four- to sixfold decrease in susceptibility the inhibition of RT activity in the presence of increasing concentrations
to AZT as compared to WT control pNL4-3. As shown of ddATP was measured. The template-primer used in this assay was
poly U-oligo (dA) and the substrate was [a-32P]dATP.previously (9), the presence of the Leu74Val mutation
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